Orexin-A is associated with increases in cerebrospinal fluid phosphorylated-tau in cognitively normal elderly subjects

Sleep

Volumn 39, Issue 6, 2016, Pages 1253-1260

  Osorio, Ricardo S ^a   Ducca, Emma L ^a   Wohlleber, Margaret E ^a   Tanzi, Emily B ^a   Gumb, Tyler ^a   Twumasi, Akosua ^a   Tweardy, Samuel ^a   Lewis, Clifton ^a   Fischer, Esther ^b   Koushyk, Viachaslau ^c   Cuartero Toledo, Maria ^a   Sheikh, Mohammed O ^a   Pirraglia, Elizabeth ^a   Zetterberg, Henrik ^d,e   Blennow, Kaj ^d   Lu, Shou En ^f   Mosconi, Lisa ^a   Glodzik, Lidia ^a   Schuetz, Sonja ^a   Varga, Andrew W ^a   Ayappa, Indu ^a   Rapoport, David M ^a   De Leon, Mony J ^a   more..

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW JERSEY NEUROSCIENCE INSTITUTE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Alzheimer disease; Orexin A; Phosphorylated tau; Sleep

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; OREXIN A; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; OREXIN; PEPTIDE FRAGMENT;

ADULT; AGED; AGING; ALZHEIMER DISEASE; APNEA HYPOPNEA INDEX; AROUSAL; ARTICLE; BRAIN FUNCTION; COGNITION ASSESSMENT; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DISEASE MARKER; FEMALE; HOME MONITORING; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; NEUROANATOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SLEEP; SLEEP DISORDERED BREATHING; SOCIAL STATUS; CEREBROSPINAL FLUID; COGNITION; EDUCATIONAL STATUS; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REGRESSION ANALYSIS; SLEEP APNEA SYNDROMES; TIME FACTOR;

AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOMARKERS; COGNITION; EDUCATIONAL STATUS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; OREXINS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; REGRESSION ANALYSIS; SLEEP; SLEEP APNEA SYNDROMES; TAU PROTEINS; TIME FACTORS;

EID: 84973449223     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.5846     Document Type: Article

References (84)

1. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-17.
2. Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-b deposition. Nature Neuroscience 2011;14:750-6.
3. Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005;48:913-22.
4. Gouras GK, Relkin NR, Sweeney D, Munoz DG, Mackenzie IR, Gandy S. Increased apolipoprotein E epsilon 4 in epilepsy with senile plaques. Ann Neurol 1997;41:402-4.
5. Mackenzie IR, Miller LA. Senile plaques in temporal lobe epilepsy. Acta Neuropathol 1994;87:504-10.
6. Horovitz SG, Braun AR, Carr WS, et al. Decoupling of the brain's default mode network during deep sleep. Proc Natl Acad Sci U S A 2009;106:11376-81.
7. Larson-Prior LJ, Power JD, Vincent JL, et al. Modulation of the brain's functional network architecture in the transition from wake to sleep. Prog Brain Res 2011;193:277-94.
8. Spoormaker VI, Schroter MS, Gleiser PM, et al. Development of a large-scale functional brain network during human non-rapid eye movement sleep. J Neurosci 2010;30:11379-87.
9. Samann PG, Wehrle R, Hoehn D, et al. Development of the brain's default mode network from wakefulness to slow wave sleep. Cereb Cortex 2011;21:2082-93.
10. Wu CW, Liu PY, Tsai PJ, et al. Variations in connectivity in the sensorimotor and default-mode networks during the first nocturnal sleep cycle. Brain Connect 2012;2:177-90.
11. Lucey BP, Bateman RJ. Amyloid-beta diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis. Neurobiol Aging 2014;35 Suppl 2:S29-34.
12. Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009;326:1005-7.
13. Li J, Llano DA, Ellis T, et al. Effect of human cerebrospinal fluid sampling frequency on amyloid-beta levels. Alzheimers Dement 2012;8:295-303.
14. Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid betaamyloid 42 in healthy middle-Aged men: a randomized clinical trial. JAMA Neurol 2014;71:971-7.
15. Slats D, Claassen JA, Verbeek MM, Overeem S. Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: focus on the role of hypocretin and melatonin. Ageing Res Rev 2013;12:188-200.
16. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science 2013;342:373-7.
17. Di MA, Joshi YB, Pratico D. Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer's disease with plaques and tangles. Neurobiol Aging 2014;35:1813-20.
18. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998;95:322-7.
19. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005;437:1257-63.
20. Hagan JJ, Leslie RA, Patel S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 1999;96:10911-6.
21. Kantor S, Mochizuki T, Janisiewicz AM, Clark E, Nishino S, Scammell TE. Orexin neurons are necessary for the circadian control of REM sleep. Sleep 2009;32:1127-34.
22. Wennstrom M, Londos E, Minthon L, Nielsen HM. Altered CSF orexin and alpha-synuclein levels in dementia patients. J Alzheimers Dis 2012;29:125-32.
23. Slats D, Claassen JA, Lammers GJ, Melis RJ, Verbeek MM, Overeem S. Association between hypocretin-1 and amyloid-beta42 cerebrospinal fluid levels in Alzheimer's disease and healthy controls. Curr Alzheimer Res 2012;9:1119-25.
24. Schmidt FM, Kratzsch J, Gertz HJ, et al. Cerebrospinal fluid melaninconcentrating hormone (MCH) and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease. PLoS One 2013;8:e63136.
25. Portelius E, Soininen H, Andreasson U, et al. Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid. Neurodegener Dis 2014;14:98-106.
26. Dauvilliers YA, Lehmann S, Jaussent I, Gabelle A. Hypocretin and brain beta-Amyloid peptide interactions in cognitive disorders and narcolepsy. Front Aging Neurosci 2014;6:119.
27. Liguori C, Romigi A, Nuccetelli M, et al. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol 2014;71:1498-505.
28. Roh JH, Jiang H, Finn MB, et al. Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease. J Exp Med 2014;211:2487-96.
29. Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord 2007;21:249-58.
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
31. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
32. De Santi S, Pirraglia E, Barr WB, et al. Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline. Neuropsychology 2008;22:469-84.
33. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York, NY: Harcourt Brace Jovanovich, 1981.
34. Wechsler D. Wechsler Adult Intelligence Scale. New York, NY: Psychological Corporation, 1955.
35. Army. Army Individual Test battery Manual of Directions and Scoring. Washington, DC: War Department, Adjutant General's Office, 1944.
36. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia, PA: Lea and Febiger, 1983.
37. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975;12:189-98.
38. Huang Y, Potter R, Sigurdson W, et al. Effects of age and amyloid deposition on abeta dynamics in the human central nervous system. Arch Neurol 2012;69:51-8.
39. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-34.
40. Ayappa I, Norman RG, Seelall V, Rapoport DM. Validation of a self-Applied unattended monitor for sleep disordered breathing. J Clin Sleep Med 2008;4:26-37.
41. Tiihonen P, Hukkanen T, Tuomilehto H, Mervaala E, Toyras J. Evaluation of a novel ambulatory device for screening of sleep apnea. Telemed J E Health 2009;15:283-9.
42. Ayappa I, Norman RG, Suryadevara M, Rapoport DM. Comparison of limited monitoring using a nasal-cannula flow signal to full polysomnography in sleep-disordered breathing. Sleep 2004;27:1171-9.
43. Lauderdale DS, Knutson KL, Yan LL, Liu K, Rathouz PJ. Selfreported and measured sleep duration: how similar are they? Epidemiology 2008;19:838-45.
44. Deuschle M, Schilling C, Leweke FM, et al. Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau. Neurosci Lett 2014;561:41-5.
45. Fronczek R, van GS, Frolich M et al. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol Aging 2012;33:1642-50.
46. Mavanji V, Perez-Leighton CE, Kotz CM, et al. Promotion of Wakefulness and Energy Expenditure by Orexin A in the Ventrolateral Preoptic Area. Sleep 2015;38:1361-70.
47. Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005;25:6716-20.
48. Mehta R, Khanday MA, Mallick BN. REM sleep loss associated changes in orexin-A levels in discrete brain areas in rats. Neurosci Lett 2015;590:62-7.
49. Espiritu JR. Aging-related sleep changes. Clin Geriatr Med 2008;24:1-14, v.
50. Benedetti F, Serretti A, Colombo C, Lorenzi C, Tubazio V, Smeraldi E. A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 2004;368:123-6.
51. Lim AS, Yu L, Kowgier M, Schneider JA, Buchman AS, Bennett DA. Modification of the relationship of the apolipoprotein E epsilon4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol 2013;70:1544-51.
52. Davies J, Chen J, Pink R, et al. Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103. Sci Rep 2015;5:12584.
53. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-92.
54. Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 2011;121:171-81.
55. Braak H, Thal DR, Ghebremedhin E, Del TK. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70:960-9.
56. Aston-Jones G, Cohen JD. An integrative theory of locus coeruleusnorepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 2005;28:403-50.
57. Bourgin P, Huitron-Resendiz S, Spier AD, et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 2000;20:7760-5.
58. Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett 1998;438:71-5.
59. Aston-Jones G, Bloom FE. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci 1981;1:876-86.
60. Horvath S, Xu X, Lake SL, Silverman EK, Weiss ST, Laird NM. Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol 2004;26:61-9.
61. Aston-Jones G, Bloom FE. Norepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli. J Neurosci 1981;1:887-900.
62. Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropath Exp Neurol 1999;58:188-97.
63. Mann DM, Yates PO, Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry 1982;45:113-9.
64. Bondareff W, Mountjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 1982;32:164-8.
65. Bondareff W. Neuropathology of nucleus basalis and locus ceruleus in Alzheimer's disease. In: Brazier MA, ed. The Biological Substrates of Alzheimer's Disease. Cambridge, UK: Academic Press, 1986:101-13.
66. Bondareff W, Mountjoy CQ, Roth M et al. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord 1987;1:256-62.
67. Bondareff W, Mountjoy CQ, Roth M. Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet 1981;1:783-4.
68. Burke WJ, Chung HD, Huang JS, et al. Evidence for retrograde degeneration of epinephrine neurons in Alzheimer's disease. Ann Neurol 1988;24:532-6.
69. Busch C, Bohl J, Ohm TG. Spatial, temporal and numeric analysis of Alzheimer changes in the nucleus coeruleus. Neurobiol Aging 1997;18:401-6.
70. Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989;287:373-92.
71. Forno LS, Norville RL. Synaptic morphology in the human locus ceruleus. Acta Neuropathol 1981;53:7-14.
72. German DC, Manaye KF, White CL III, et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 1992;32:667-76.
73. Hardy J, Adolfsson R, Alafuzoff I, et al. Transmitter deficits in Alzheimer's disease. Neurochem Int 1985;7:545-63.
74. Hoogendijk WJ, Pool CW, Troost D, van ZE, Swaab DF. Image analyser-Assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain 1995;118:131-43.
75. Ichimiya Y, Arai H, Kosaka K, Iizuka R. Morphological and biochemical changes in the cholinergic and monoaminergic systems in Alzheimer-type dementia. Acta Neuropathol 1986;70:112-6.
76. Iversen LL, Rossor MN, Reynolds GP, et al. Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neurosci Lett 1983;39:95-100.
77. Marcyniuk B, Mann DM, Yates PO. The topography of cell loss from locus caeruleus in Alzheimer's disease. J Neurol Sci 1986;76:335-45.
78. Strong R, Huang JS, Huang SS, Chung HD, Hale C, Burke WJ. Degeneration of the cholinergic innervation of the locus ceruleus in Alzheimer's disease. Brain Res 1991;542:23-8.
79. Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 2007;28:327-35.
80. Gannon M, Che P, Chen Y, Jiao K, Roberson ED, Wang Q. Noradrenergic dysfunction in Alzheimer's disease. Front Neurosci 2015;9:220.
81. Bright J, Hussain S, Dang V, et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging 2015;36:693-709.
82. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012;11:1048-56.
83. Alcolea D, Martinez-Lage P, Sanchez-Juan P, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurol 2015;85:626-33.
84. Osorio RS, Ayappa I, Mantua J, et al. The interaction between sleepdisordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. Neurobiol Aging 2013;35:1318-24.